01.31.14
IlluminOss Medical has launched its proprietary Photodynamic Bone Stabilization System (PBSS) in Spain and Israel. The East Providence, R.I.-based firm's PBSS is a percutaneous, patient-specific orthopedic implant system for the stabilization and treatment of bone fractures. The system will be sold through distribution agreements.
"We look forward to expanding access to this technology, which can significantly enhance how orthopedic fractures are treated, in Spain and Israel," said Dirk Kuyper, president and CEO of IlluminOss. "We are now commercially available in eight countries, providing patients and surgeons with an innovative and unprecedented fracture repair system."
With CE marking for light to low-load bearing indications, IlluminOss' PBSS is used in Germany, Austria, Switzerland, Italy, Turkey and the Netherlands, in addition to Spain and Israel.IlluminOss currently is pursuing U.S. FDA approval as well as an expansion of its indications in the European Union.
The minimally invasive PBSS enables clinicians to repair bone fractures using a light-curable polymer contained within an expandable balloon catheter to achieve bone stabilization. The procedure is made through a small percutaneous surgical approach providing a customized method of orthopedic bone stabilization.
IlluminOss Medical is privately held and is currently focused on commercializing its PBSS technology. Founded in 2007, the company is funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
"We look forward to expanding access to this technology, which can significantly enhance how orthopedic fractures are treated, in Spain and Israel," said Dirk Kuyper, president and CEO of IlluminOss. "We are now commercially available in eight countries, providing patients and surgeons with an innovative and unprecedented fracture repair system."
With CE marking for light to low-load bearing indications, IlluminOss' PBSS is used in Germany, Austria, Switzerland, Italy, Turkey and the Netherlands, in addition to Spain and Israel.IlluminOss currently is pursuing U.S. FDA approval as well as an expansion of its indications in the European Union.
The minimally invasive PBSS enables clinicians to repair bone fractures using a light-curable polymer contained within an expandable balloon catheter to achieve bone stabilization. The procedure is made through a small percutaneous surgical approach providing a customized method of orthopedic bone stabilization.
IlluminOss Medical is privately held and is currently focused on commercializing its PBSS technology. Founded in 2007, the company is funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.